News

TEDCO Announces Investment into Astek Diagnostics

TEDCO, Maryland’s economic engine for technology companies, announced a Seed Funds investment of $250,000 into Astek Diagnostics, a life sciences company fighting antibiotic resistance through innovative technology. In addition to this investment through the Life Sciences Investment Fund – a funding opportunity under the umbrella of TEDCO’s Seed Funds – Astek Diagnostics has received an additional $325,000 from the State Small Business Credit Initiative (SSBCI) funding.

Mustafa Al-Adhami“Without the proper diagnostic procedures, patients and physicians risk advancing the vicious cycle of antibiotic resistance,” explained Mustafa Al-Adhami, PhD, CEO of Astek Diagnostics. “This cycle leads to the creation of more resilient bacteria that require more complicated treatments. But with the help of our device, the Jiddu, we can put an end to this disastrous cycle. The Jiddu provides physicians with more diagnostic material, allowing them to make informed decisions about the best prescribing methods to use.”

Astek Diagnostics, based in Baltimore, Md., is a business that is focused on creating a platform to determine antibiotic sensitivity. Through this venture, the company developed the Jiddu. This device is a cost-effective and efficient diagnostic platform that provides physicians with adequate accurate information to diagnose and treat urinary tract infections, finding any antibiotic susceptibility and preventing the use of ineffective or excessive antibiotics—a practice that can cause the creation of antibiotic resistant bacteria.

Astek Diagnostics“The issue of bacteria resiliency affects us all,” said Teddy Gresser, director of Seed Funds at TEDCO. “Astek’s determination to fight against antibiotic resistance has potential to not only be a successful business venture, but also to change the way physicians operate, allowing for more accuracy and less complications. TEDCO is eager to witness Astek Diagnostics’ journey, what innovations they can create, and how their business will impact Maryland.”

Astek is a long-standing TEDCO portfolio company, having received funding from TEDCO’s Pre-Seed Builder Fund, Maryland Innovation Initiative (MII), and successfully participated in TEDCO’s SBIR/STTR Proposal Lab.

The Seed Fund is one of the many funding opportunities available through TEDCO; for information on other opportunities, or information on how to apply, entrepreneurs should visit https://www.tedcomd.com/funding.

Recent News

04/01/2025

ReAlta Life Sciences Announces Appointment of Distinguished Immunologist, Laurie Glimcher, M.D., to Board of Directors

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases,  announced the appointment of Laurie Glimcher, M.D., to its Board of Directors, effective immediately. Dr. Glimcher is a distinguished immunologist widely renowned for her work in cancer

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and